Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jun;64(6):1482-1492.
doi: 10.1111/epi.17608. Epub 2023 Apr 16.

Phenobarbital in super-refractory status epilepticus (PIRATE): A retrospective, multicenter analysis

Stefan Kunst  1 , Mikel Rojo  1 , Moritz L Schmidbauer  1 , Johann O Pelz  2 , Annekatrin Mueller  2 , Jens Minnerup  3 , Lennart Meyer  3 , Dominik Madžar  4 , Caroline Reindl  4 , Marie Madlener  5 , Michael Malter  5 , Bernhard Neumann  6   7 , Konstantinos Dimitriadis  1   8 ; IGNITE Study Group
Affiliations
Multicenter Study

Phenobarbital in super-refractory status epilepticus (PIRATE): A retrospective, multicenter analysis

Stefan Kunst et al. Epilepsia. 2023 Jun.

Abstract

Objective: Super-refractory status epilepticus (SRSE) is an enduring or recurring SE after 24 h or more of general anesthesia. This study aimed to evaluate the efficacy and safety of phenobarbital (PB) for the treatment of SRSE.

Methods: This retrospective, multicenter study included neurointensive care unit (NICU) patients with SRSE treated with PB between September 2015 and September 2020 from six participating centers of the Initiative of German NeuroIntensive Trial Engagement (IGNITE) to evaluate the efficacy and safety of PB treatment for SRSE. The primary outcome measure was seizure termination. In addition, we evaluated maximum reached serum levels, treatment duration, and clinical complications using a multivariate generalized linear model.

Results: Ninety-one patients were included (45.1% female). Seizure termination was achieved in 54 patients (59.3%). Increasing serum levels of PB were associated with successful seizure control (per μg/mL: adjusted odds ratio [adj.OR] = 1.1, 95% confidence interval [CI] 1.0-1.2, p < .01). The median length of treatment in the NICU was 33.7 [23.2-56.6] days across groups. Clinical complications occurred in 89% (n = 81) of patients and included ICU-acquired infections, hypotension requiring catecholamine therapy, and anaphylactic shock. There was no association between clinical complications and treatment outcome or in-hospital mortality. The overall average modified Rankin scale (mRS) at discharge from the NICU was 5 ± 1. Six patients (6.6%) reached mRS ≤3, of whom five were successfully treated with PB. In-hospital mortality was significantly higher in patients in whom seizure control could not be achieved.

Significance: We observed a high rate in attainment of seizure control in patients treated with PB. Success of treatment correlated with higher dosing and serum levels. However, as one would expect in a cohort of critically ill patients with prolonged NICU treatment, the rate of favorable clinical outcome at discharge from the NICU remained extremely low. Further prospective studies evaluating long-term clinical outcome of PB treatment as well as an earlier use of PB at higher doses would be of value.

Keywords: SRSE; phenobarbital; super-refractory status epilepticus.

PubMed Disclaimer

References

REFERENCES

    1. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus-report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56(10):1515-23.
    1. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134(Pt 10):2802-18.
    1. Chateauneuf AL, Moyer JD, Jacq G, Cavelot S, Bedos JP, Legriel S. Super-refractory status epilepticus: epidemiology, early predictors, and outcomes. Intensive Care Med. 2017;43(10):1532-4.
    1. Delaj L, Novy J, Ryvlin P, Marchi NA, Rossetti AO. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurol Scand. 2017;135(1):92-9.
    1. Kantanen AM, Kalviainen R, Parviainen I, Ala-Peijari M, Bäcklund T, Koskenkari J, et al. Predictors of hospital and one-year mortality in intensive care patients with refractory status epilepticus: a population-based study. Crit Care. 2017;21(1):71.

Publication types

LinkOut - more resources